# Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

> **NCT04233294** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Camrelizumab
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT04233294
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-02
- **Primary completion:** 2024-02
- **Final completion:** 2026-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233294, "Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04233294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*